Aeras Global TB Vaccine Foundation

19 articles about Aeras Global TB Vaccine Foundation

• 

  As UN Summit Addresses Global Tuberculosis Pandemic, GSK Touts Effective Vaccine

  9/26/2018

  GlaxoSmithKline (GSK) and the non-profit Aeras reported that their M72/AS01E vaccine candidate significantly cut the rate of pulmonary tuberculosis in HIV-negative adults with latent tuberculosis infection.

• Aeras Global TB Vaccine Foundation, GlaxoSmithKline Collaborate on TB Vaccine

  10/10/2012

• Aeras Global TB Vaccine Foundation and Infectious Disease Research Institute (IDRI) Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine

  5/10/2012

• Aeras Global TB Vaccine Foundation and CanSino to Collaborate on TB Vaccine Development

  5/7/2012

• TapImmune Inc. and Aeras Global TB Vaccine Foundation Start Research & Development Collaboration

  10/31/2011

• Aeras Global TB Vaccine Foundation and Crucell N.V. Announce Phase II Clinical Trial Start in Kenya

  9/22/2010

• Aeras Global TB Vaccine Foundation And Crucell N.V. Announce Start of Phase II TB study in South Africa

  4/14/2010

• TapImmune Inc. Signs R&D Collaboration Letter of Intent Agreement With Aeras Global TB Vaccine Foundation

  2/1/2010

• Aeras Global TB Vaccine Foundation And Crucell N.V. Announce Start of TB Infant Study in South Africa

  4/28/2009

• Aeras Global TB Vaccine Foundation and Crucell N.V. Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa

  10/17/2008

• Emergent BioSolutions and the University of Oxford form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust Sanger Institute and Aeras Global TB Vaccine Foundation

  7/23/2008

• Aeras Global TB Vaccine Foundation, Crucell N.V. and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa

  4/9/2008

• Aeras Global TB Vaccine Foundation and Crucell N.V. Announce Start of a Tuberculosis Vaccine Clinical Trial in the United States. Aeras Global TB Vaccine Foundation Commits a Further USD 5M to the Development of the Tuberculosis Vaccine

  12/21/2007

• Crucell N.V., Aeras Global TB Vaccine Foundation, and SATVI Announce Start of Tuberculosis Vaccine Clinical Trial in South Africa Six Months After Launching Initial Trial in the United States

  5/11/2007

• The Netherlands Invest EUR 18.4 Million To Develop Better Vaccines To Fight Raging TB Pandemic

  11/3/2006

• Crucell N.V. And Aeras Global TB Vaccine Foundation Announce Start Of Tuberculosis Vaccine Clinical Trial

  10/25/2006

• Omnia Biologics, Inc. And Aeras Global TB Vaccine Foundation Sign Master Services Agreement

  7/19/2006

• GlaxoSmithKline And Aeras Global TB Vaccine Foundation Partner To Develop New TB Vaccine

  10/21/2005

• Aeras Global TB Vaccine Foundation Release: Clinical Trial Of A New TB Vaccine In The U.S. Begins; New Vaccine May Prove More Potent Than 100-Year-Old Current Vaccine

  2/18/2004